This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ChemoCentryx Dirección

Dirección controles de criterios 1/4

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

CEO

ChemoCentryx no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yi Yau	Senior VP of Finance & Principal Accounting Officer	less than a year	sin datos	sin datos
William Slattery	Vice President of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Kari Leetch	Senior Vice President of Human Resources	2.6yrs	sin datos	sin datos
Sangita Ghosh	Senior Vice President of Technical Operations	2.6yrs	sin datos	sin datos

2.6yrs

Permanencia media

Equipo directivo experimentado: 2CX's management team is considered experienced (2.6 years average tenure).

This company listing is no longer active

ChemoCentryx Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Chemocentryx, Inc. Announces Executive Changes

Chemocentryx, Inc. Announces Appointment of Jennifer L. Herron to Board as Independent Director

ChemoCentryx, Inc. Appoints Yi Ching Yau as Senior Vice President, Finance and Principal Accounting Officer

ChemoCentryx Announces Changes to its Board of Directors

Insufficient new directors

ChemoCentryx, Inc., Annual General Meeting, May 26, 2022

Recent updates

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders.

Chemocentryx, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.56 loss in 2Q 2021)

Amgen Inc. (NasdaqGS:AMGN) entered into a definitive agreement to acquire ChemoCentryx, Inc. (NasdaqGS:CCXI) for $3.7 billion.

ChemoCentryx, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Chemocentryx, Inc. Announces Appointment of Jennifer L. Herron to Board as Independent Director

ChemoCentryx, Inc. Appoints Yi Ching Yau as Senior Vice President, Finance and Principal Accounting Officer

Chemocentryx Inc. Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered Pd-L1 Inhibitor, Ccx559, At the 2022 American Society of Clinical Oncology (Asco) Annual Meeting

ChemoCentryx Announces Changes to its Board of Directors

First quarter 2022 earnings released: US$0.55 loss per share (vs US$0.43 loss in 1Q 2021)

Insufficient new directors

ChemoCentryx, Inc. Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, Ccx559, At American Association for Cancer Research (Aacr) Annual Meeting 2022

ChemoCentryx, Inc., Annual General Meeting, May 26, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

ChemoCentryx, Inc. to Report Q4, 2021 Results on Mar 01, 2022

ChemoCentryx, Inc Announces EU Approval of Tavneos® (Avacopan) for the Treatment of ANCA-Associated Vasculitis

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.35 loss in 3Q 2020)

ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.32 profit in 2Q 2020)

Rosen Law Firm Encourages ChemoCentryx, Inc. Investors with Losses to Secure Counsel Before Important July 6, 2021 Deadline in Securities Class Action

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed against ChemoCentryx, Inc

Executive VP & COO recently bought €99k worth of stock

ChemoCentryx Announces Results of U.S. Food and Drug Administration Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against ChemoCentryx, Inc

First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.35 loss in 1Q 2020)

Director recently sold €1.5m worth of stock

ChemoCentryx, Inc Appoint Susan M. Kanaya to the Board of Directors

ChemoCentryx, Inc. Appoints Tausif Butt as Executive Vice President and Chief Operating Officer

Full year 2020 earnings released: US$0.84 loss per share (vs US$0.97 loss in FY 2019)

Revenue misses expectations

Chemocentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer

ChemoCentryx, Inc. to Report Q4, 2020 Results on Mar 01, 2021

ChemoCentryx Announces Publication in the New England Journal of Medicine of Results of the Pivotal Phase III Advocate Trial of Avacopan for the Treatment of Anca-Associated Vasculitis

New 90-day high: €54.18

Independent Director recently sold €1.0m worth of stock

Independent Director recently sold €1.3m worth of stock

ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate

New 90-day high: €49.12

New 90-day high: €47.85

New 90-day high: €47.06

Third quarter 2020 earnings released: US$0.35 loss per share

Revenue misses expectations

ChemoCentryx, Inc. to Report Q3, 2020 Results on Nov 09, 2020

ChemoCentryx, Inc. Announces Positive Topline Results of Phase II Aurora Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)

ChemoCentryx, Inc. Announces FDA Acceptance of the Avacopan New Drug Application for the Treatment of ANCA-Associated Vasculitis

New 90-day low - €42.71

First half earnings released

ChemoCentryx, Inc. to Report Q2, 2020 Results on Aug 10, 2020

ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from Russell Microcap Index

CEO

Equipo directivo

Permanencia media